Lipids produced within the thymus give immune cells the initial boost they need to fight off infection

September 12, 2012, Agency for Science, Technology and Research (A*STAR), Singapore
Immunology: The kick-starters of immune cells
The thymus is a central component of the immune system, and is the site where selected iNKT cells undergo initial activation before migrating to other sites in the body. Credit: iStockphoto.com/janulla

Semi-invariant natural killer T (iNKT) cells wage war against infectious threats, attacking microbial cells and generating signals that enable other immune cells also to respond aggressively. iNKT cells initially undergo activation in the thymus; after being 'switched on' via interaction with certain antigens, they undergo an initial population expansion and then migrate to peripheral immune sites where they proliferate further so they can mount an effective defense.

Some of these activating triggers are foreign in origin, such as bacterial membrane components. However, iNKT cells can also be activated by lipids produced within the thymus itself, as demonstrated in new research from a team led by Gennaro De Libero of the A*STAR Singapore Immunology Network. Previous research had indicated that such 'self' lipids might be an important stimulus. De Libero's team therefore began by treating cultured mouse iNKT cells with lipids isolated from thymic cells and looking for biological signatures of activation. "We found that unusual lipids are important for thymic selection, and that these lipids are produced within unique called peroxisomes," he says.

A peroxisomal enzyme called glyceronephosphate O-acyltransferase (GNPAT) plays a central role in producing these particular lipids. Accordingly, the researchers observed that iNKT cell maturation tended to stall in mice lacking GNPAT, and these animals had considerably fewer functional iNKT cells than normal mice. Subsequent transplantation experiments demonstrated that immature iNKT cells from wild-type mice are less likely to reach full maturity when grafted into thymuses of GNPAT-deficient mice. Collectively, these experiments demonstrate that a substantial subset of developing iNKT cells is dependent on interactions with peroxisomally produced lipids in the thymus in order to undergo full activation.

Despite the team's revelation of  insightful details about the development of these important , a number of mysteries remain—for example, how mature iNKTs learn to stop targeting the that switched them on in the first place. "Now that we know the stimulatory self lipids, we can address the mechanisms which reduce iNKT reactivity against them in the periphery," explains De Libero. This would provide a means to avoid autoimmune attacks.

In parallel, he and his colleagues intend to determine whether foreign lipids also trigger immune cell maturation via a similar mechanism. "For example, T cells that recognize mycobacterial lipids are important in protecting people from tuberculosis," he says, "and it will be important to study how these cells are selected and mature within the thymus."

Explore further: Scientists discover special class of natural fats stimulates immune cells to fight diseases

More information: Facciotti, F., Ramanjaneyulu, G. S., Lepore, M., Sansano, S., Cavallari, M., et al. Peroxisome-derived lipids are self antigens that stimulate invariant natural killer T cells in the thymus. Nature Immunology 13, 474–480 (2012). www.nature.com/ni/journal/v13/n5/abs/ni.2245.html

Related Stories

Scientists discover special class of natural fats stimulates immune cells to fight diseases

April 2, 2012
An international research team led by scientists from Singapore Immunology Network (SIgN) under the Agency of Science, Technology and Research (A*STAR) discovered that a special class of fatty molecules is essential for activating ...

Research describes advantages of new vaccine adjuvant

December 12, 2011
New research from the laboratory of Dr. Elizabeth Leadbetter at the Trudeau Institute may lead to a whole new class of vaccines. Dr. Leadbetter's lab has discovered new properties of a potential vaccine adjuvant that suggest ...

Improving psoriasis with GLP-1 analogue therapy

December 13, 2011
(Medical Xpress) -- UCD clinician scientists and researchers from NUI Maynooth and Trinity College led by Conway Fellow, Professor Donal O’Shea have reported an improvement in the severity of psoriasis in patients following ...

Recommended for you

Improving vaccines for the elderly by blocking inflammation

January 22, 2018
By identifying why skin immunity declines in old age, a UCL-led research team has found that an anti-inflammatory pill could help make vaccines more effective for elderly people.

Novel genomic tools provide new insight into human immune system

January 19, 2018
When the body is under attack from pathogens, the immune system marshals a diverse collection of immune cells to work together in a tightly orchestrated process and defend the host against the intruders. For many decades, ...

First vaccine developed against grass pollen allergy

January 18, 2018
Around 400 million people worldwide suffer in some form or other from a grass pollen allergy (rhinitis), with the usual symptoms of runny nose, cough and severe breathing problems. In collaboration with the Viennese firm ...

Genomics reveals key macrophages' involvement in systemic sclerosis

January 18, 2018
A new international study has made an important discovery about the key role of macrophages, a type of immune cell, in systemic sclerosis (SSc), a chronic autoimmune disease which currently has no cure.

Researchers discover key driver of atopic dermatitis

January 17, 2018
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes ...

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.